Complement Split Products in Amniotic Fluid in Pregnancies Subsequently Developing Early-Onset Preeclampsia

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Banadakoppa, Manu ^a   Vidaeff, Alex C ^a   Yallampalli, Uma ^a   Ramin, Susan M ^a   Belfort, Michael A ^a   Yallampalli, Chandra ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A;

ADULT; AMNIOCENTESIS; AMNION FLUID ANALYSIS; ARTICLE; CASE CONTROL STUDY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; IMMUNE DYSREGULATION; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SECOND TRIMESTER PREGNANCY; AMNION FLUID; IMMUNOLOGY; MIDDLE AGED; PRE-ECLAMPSIA;

ADULT; AMNIOTIC FLUID; CASE-CONTROL STUDIES; COMPLEMENT C4A; COMPLEMENT C5A; COMPLEMENT FACTOR B; FEMALE; HUMANS; MIDDLE AGED; PRE-ECLAMPSIA; PREGNANCY;

EID: 84947983497     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/263109     Document Type: Article

References (39)

1. J. M. Roberts and H. S. Gammill, "Preeclampsia: recent insights," Hypertension, vol. 46, no. 6, pp. 1243-1249, 2005.
2. A.-K. Wikström, A. Larsson, U. J. Eriksson, P. Nash, S. Nordén-Lindeberg, and M. Olovsson, "Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia," Obstetrics&Gynecology, vol. 109, no. 6, pp. 1368-1374, 2007.
3. H. Valensise, B. Vasapollo, G. Gagliardi, andG.P. Novelli, "Early and Late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease," Hypertension, vol. 52, no. 5, pp. 873-880, 2008.
4. D. Sinha, M. Wells, and W. P. Faulk, "Immunological studies of human placentae: complement components in pre-eclamptic chorionic villi," Clinical and Experimental Immunology, vol. 56, no. 1, pp. 175-184, 1984.
5. M. Haeger, M. Unander, and A. Bengtsson, "Complement activation in relation to development of preeclampsia," Obstetrics and Gynecology, vol. 78, no. 1, pp. 46-49, 1991.
6. E. Soto, R. Romero, K. Richani et al., "Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products," Journal of Maternal-Fetal and Neonatal Medicine, vol. 23, no. 7, pp. 646-657, 2010.
7. A.M. Lynch, J. R. Murphy, R. S. Gibbs et al., "The interrelationship of complement-activation fragments and angiogenesisrelated factors in early pregnancy and their associationwith preeclampsia," BJOG, vol. 117, no. 4, pp. 456-462, 2010.
8. R. Boij, J. Svensson, K. Nilsson-Ekdahl et al., "Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia," American Journal of Reproductive Immunology, vol. 68, no. 3, pp. 258-270, 2012.
9. G. Girardi, R. Bulla, J. E. Salmon, and F. Tedesco, "The complement system in the pathophysiology of pregnancy," Molecular Immunology, vol. 43, no. 1-2, pp. 68-77, 2006.
10. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy, "Hypertension in pregnancy," Obstetrics & Gynecology, vol. 122, no. 5, pp. 1122-1131, 2013.
11. S. Gallucci and P. Matzinger, "Danger signals: SOS to the immune system," Current Opinion in Immunology, vol. 13, no. 1, pp. 114-119, 2001.
12. Z. Derzsy, Z. Prohászka, J. Rigó Jr., G. Füst, and A. Molvarec, "Activation of the complement system in normal pregnancy and preeclampsia,"Molecular Immunology, vol. 47, no. 7-8, pp. 1500-1506, 2010.
13. K. Richani, E. Soto, R. Romero et al., "Normal pregnancy is characterized by systemic activation of the complement system," Journal of Maternal-Fetal and Neonatal Medicine, vol. 17, no. 4, pp. 239-245, 2005.
14. S. M. Caucheteux, C. Kanellopoulos-Langevin, and D. M. Ojcius, "At the innate frontiers between mother and fetus: linking abortion with complement activation," Immunity, vol. 18, no. 2, pp. 169-172, 2003.
15. K. Richani, R. Romero, E. Soto et al., "Unexplained intrauterine fetal death is accompanied by activation of complement," Journal of Perinatal Medicine, vol. 33, no. 4, pp. 296-305, 2005.
16. E. Soto, R. Romero, K. Richani et al., "Anaphylatoxins inpreterm and term labor," Journal of Perinatal Medicine, vol. 33, no. 4, pp. 306-313, 2005.
17. A. M. Lynch and J. E. Salmon, "Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications," Placenta, vol. 31, no. 7, pp. 561-567, 2010.
18. M. Haeger, A. Bengtson, K. Karlsson, and M. Heideman, "Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid," Obstetrics and Gynecology, vol. 73, no. 4, pp. 551-556, 1989.
19. M. Haeger, M. Unander, B. Norder-Hansson, M. Tylman, and A. Bengtsson, "Complement, neutrophil, and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count," Obstetrics & Gynecology, vol. 79, no. 1, pp. 19-26, 1992.
20. K. J. Denny, L. G. Coulthard, R. H. Finnell, L. K. Callaway, S.M. Taylor, and T. M. Woodruff, "Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia," Journal of Reproductive Immunology, vol. 97, no. 2, pp. 211-216, 2013.
21. A. M. Lynch, R. S. Gibbs, J. R. Murphy, P. C. Giclas, J. E. Salmon, and V. M. Holers, "Early elevations of the complement activation fragment C3a and adverse pregnancy outcomes," Obstetrics and Gynecology, vol. 117, no. 1, pp. 75-83, 2011.
22. A. M. Lynch, R. H. Eckel, J. R. Murphy et al., "Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia," American Journal of Obstetrics and Gynecology, vol. 206, no. 5, pp. 428.e1-428.e8, 2012.
23. D. Cohen, A. Buurma, N. N. Goemaere et al., "Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss," The Journal of Pathology, vol. 225, no. 4, pp. 502-511, 2011.
24. A. Buurma, D. Cohen, K. Veraar et al., "Preeclampsia is characterized by placental complement dysregulation," Hypertension, vol. 60, no. 5, pp. 1332-1337, 2012.
25. A. M. Lynch, J. R. Murphy, T. Byers et al., "Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia," American Journal of Obstetrics and Gynecology, vol. 198, no. 4, pp. 385.e1-385.e9, 2008.
26. E. Soto, R. Romero, K. Richani et al., "Evidence for complement activation in the amniotic fluid of women with spontaneous preterm labor and intra-amniotic infection," Journal of Maternal-Fetal and Neonatal Medicine, vol. 22, no. 11, pp. 983-992, 2009.
27. E. Vaisbuch, R. Romero, O. Erez et al., "Fragment Bb in amniotic fluid: Evidence for complement activation by the alternative pathway in women with intra-amniotic infection/ inflammation," The Journal ofMaternal-Fetal and Neonatal Medicine, vol. 22, no. 10, pp. 905-916, 2009.
28. K. E. Lillegard, A. C. Johnson, S. J. Lojovich et al., "Complement activation is critical for placental ischemia-induced hypertension in the rat,"Molecular Immunology, vol. 56, no. 1-2, pp.91-97, 2013.
29. G. Girardi, J. Berman, P. Redecha et al., "Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome," The Journal of Clinical Investigation, vol. 112, no. 11, pp. 1644-1654, 2003.
30. G. Girardi, D. Yarilin, J. M. Thurman, V. M. Holers, and J. E. Salmon, "Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction,"The Journal of Experimental Medicine, vol. 203, no. 9, pp. 2165-2175, 2006.
31. I. Stabile, K. H. Nicolaides, A. Bach et al., "Complement factors in fetal and maternal blood and amniotic fluid during the second trimester of normal pregnancy," British Journal of Obstetrics and Gynaecology, vol. 95, no. 3, pp. 281-285, 1988.
32. A. Frey, G. Ertl, C. E. Angermann, U. Hofmann, S. Störk, and S. Frantz, "Complement C3c as a biomarker in heart failure," Mediators of Inflammation, vol. 2013, Article ID716902, 7 pages, 2013.
33. F. Tedesco, G. Narchi, O. Radillo, S. Meri, S. Ferrone, and C. Betterle, "Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins," The Journal of Immunology, vol. 151, no. 3, pp. 1562-1570, 1993.
34. J. E. Salmon, C. Heuser, M. Triebwasser et al., "Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort," PLoS Medicine, vol. 8, no. 3, Article ID e1001013, 2011.
35. J. S. Gilbert, C. T. Banek, V. L. Katz, S. A. Babcock, and J. F. Regal, "Complement activation in pregnancy: too much of a good thing?" Hypertension, vol. 60, no. 5, pp. 1114-1116, 2012.
36. R. M. Burwick and B. B. Feinberg, "Eculizumab for the treatment of preeclampsia/HELLP syndrome," Placenta, vol. 34, no. 2, pp. 201-203, 2013.
37. G. Girardi, P. Redecha, and J. E. Salmon, "Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation," Nature Medicine, vol. 10, no. 11, pp. 1222-1226, 2004.
38. M.A. Rodger, N. J. Langlois, J. I.deVries et al., "Low-molecularweight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM)," Systematic Reviews, vol. 3, article 69, 2014.
39. W. Wang, R. A. Irani, Y. Zhang et al., "Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia," Hypertension, vol. 60, no. 3, pp. 712-721, 2012.